We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Endocarditis Postsurgical Risk Higher in Drug Addicts

By HospiMedica International staff writers
Posted on 15 Sep 2015
Injection drug users who undergo surgery for infective endocarditis (IE) have a 10 times higher risk of reoperation or death following surgery compared to those who do not, according to a new study. More...


Researchers at the Cleveland Clinic (CC; OH, USA) conducted a study to evaluate the effect of active ongoing injection drug use (IDU) on outcomes after operation for IE. Of the 536 IE patients identified from the CC Infective Endocarditis and Cardiovascular Information registries surgically treated at the CC during the five-year study period, 41 (8%) were actively injected drugs. The primary outcome of the study was death or reoperation for IE.

The results showed that patients who injected drugs had poorer survival free of reoperation, with the risk of events varied with time; 90–180 days after surgery, injection drug abusers had 10 times the risk of death or reoperation for IE than the patients who did not inject drugs. Before or after that time, all patients appeared to have similar risk for death or reoperation. They also found that while in IDU-patients reoperation and death contributed equally to outcome, reoperation for IE was far less common among those that did not abuse drugs. The study was published in the September 2015 issue of the Annals of Thoracic Surgery.

“Injecting drugs into the bloodstream carries with it the potential for inadvertently introducing microorganisms which can settle on heart valves and cause IE,” said lead author Nabin Shrestha, MD, MPH. “Our hope is that this study can help patients with IDU and their doctors understand the magnitude of risk for endocarditis relapse during this time period and convince policy makers that IE treatment without adequately addressing the underlying addiction prevents achieving outcomes that should otherwise be attainable.”

IE is defined as an infection of the endocardial surface of the heart, which may include one or more heart valves, the mural endocardium, or a septal defect. Intracardiac effects include severe valvular insufficiency, which may lead to intractable congestive heart failure (CHF) and myocardial abscesses. Historically, the main risk factor for IE was rheumatic heart disease, but recent research has shown that other risk factors have gained prominence, such as IDU, prosthetic valve infection, degenerative valvular disease, and hemodialysis.

Related Links:

Cleveland Clinic



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Syringes
Prefilled Saline Flush Syringes
Electric Bed
DIXION Intensive Care Bed
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.